The deubiquitinating enzyme UCHL3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway

[1]  Yinlu Ding,et al.  OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer , 2022, Oncogene.

[2]  Jun Zhou,et al.  MINDY1 promotes bladder cancer progression by stabilizing YAP , 2021, Cancer Cell International.

[3]  Jianing Tang,et al.  SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer , 2021, International journal of biological sciences.

[4]  Junhu Wan,et al.  YAP in pancreatic cancer: oncogenic role and therapeutic strategy , 2021, Theranostics.

[5]  G. Blandino,et al.  Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. , 2020, Cancer letters.

[6]  E. Sturgis,et al.  Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. , 2020, JAMA oncology.

[7]  D. O'Brien,et al.  The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma , 2020, Molecular Cancer Research.

[8]  Na Liu,et al.  The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor , 2020, Signal Transduction and Targeted Therapy.

[9]  P. Ascierto,et al.  PD-1 Blockade in Anaplastic Thyroid Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Dogan,et al.  Dissecting Anaplastic Thyroid Carcinoma (ATC): A Comprehensive Clinical, histologic, Immunophenotypic, and Molecular Study of 360 Cases. , 2020, Thyroid : official journal of the American Thyroid Association.

[11]  I. Bahar,et al.  EIF3H Orchestrates Hippo Pathway–Mediated Oncogenesis via Catalytic Control of YAP Stability , 2020, Cancer Research.

[12]  Qiaojun He,et al.  USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ , 2020, Cancer Research.

[13]  Lidong Wang,et al.  Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2 , 2020, Theranostics.

[14]  Jinbao Liu,et al.  SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression , 2020, Theranostics.

[15]  X. Yang,et al.  Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187 , 2020, Oncogenesis.

[16]  A. Pobbati,et al.  A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy , 2020, Theranostics.

[17]  Zihua Chen,et al.  EphA2‐to‐YAP pathway drives gastric cancer growth and therapy resistance , 2020, International journal of cancer.

[18]  Lidong Wang,et al.  SHARPIN Inhibits Esophageal Squamous Cell Carcinoma Progression by Modulating Hippo Signaling , 2019, Neoplasia.

[19]  Anping Li,et al.  SIX1 Activates STAT3 Signaling to Promote the Proliferation of Thyroid Carcinoma via EYA1 , 2019, Front. Oncol..

[20]  Yi Yang,et al.  USP47-mediated deubiquitination and stabilization of YAP contributes to the progression of colorectal cancer , 2019, Protein & Cell.

[21]  Jie Gao,et al.  UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway , 2019, Oncogene.

[22]  Zhiwang Song,et al.  UCHL3 promotes pancreatic cancer progression and chemo-resistance through FOXM1 stabilization. , 2019, American journal of cancer research.

[23]  Chunling Yi,et al.  YAP/TAZ Signaling and Resistance to Cancer Therapy. , 2019, Trends in cancer.

[24]  Chen Ding,et al.  OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. , 2019, Molecular cell.

[25]  G. Halder,et al.  Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine , 2018, Nature Reviews Molecular Cell Biology.

[26]  J. Crawford,et al.  Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review , 2018, Expert opinion on therapeutic patents.

[27]  T. Blundell,et al.  The deubiquitylating enzyme UCHL3 regulates Ku80 retention at sites of DNA damage , 2018, Scientific Reports.

[28]  R. Pili,et al.  Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer , 2018, Free radical biology & medicine.

[29]  M. Stuschke,et al.  Anaplastic thyroid carcinoma: review of treatment protocols. , 2018, Endocrine-related cancer.

[30]  Z. Lou,et al.  The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization , 2017, Oncogene.

[31]  M. Javid,et al.  Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer , 2017, Molecular and Cellular Endocrinology.

[32]  A. Ribechini,et al.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies , 2017, Nature Reviews Endocrinology.

[33]  A. H. Smits,et al.  An Interaction Landscape of Ubiquitin Signaling. , 2017, Molecular cell.

[34]  G. Mills,et al.  Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. , 2016, American journal of cancer research.

[35]  B. Hinz,et al.  YAP1 Is a Driver of Myofibroblast Differentiation in Normal and Diseased Fibroblasts. , 2015, The American journal of pathology.

[36]  Bin Zhao,et al.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.

[37]  A. Bauer,et al.  YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors , 2015, Hepatology.

[38]  T. Pawlik,et al.  Emerging role of Hpo signaling and YAP in hepatocellular carcinoma , 2015, Journal of hepatocellular carcinoma.

[39]  Q. Dou,et al.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review , 2015, Expert opinion on therapeutic patents.

[40]  M. Karin,et al.  A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis , 2015, Genes & development.

[41]  Jae Eun Lee,et al.  Ubiquitin C-terminal hydrolase-L3 regulates EMT process and cancer metastasis in prostate cell lines. , 2014, Biochemical and biophysical research communications.

[42]  G. G. Galli,et al.  The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. , 2014, Cancer cell.

[43]  K. Guan,et al.  The Hippo signaling pathway in stem cell biology and cancer , 2014, EMBO reports.

[44]  Xin Zheng,et al.  Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma , 2014, Molecular Cancer.

[45]  Y. Nikiforov,et al.  American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.

[46]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[47]  C. Vandevoort,et al.  Essential role of ubiquitin C‐terminal hydrolases UCHL1 and UCHL3 in mammalian oocyte maturation , 2012, Journal of cellular physiology.

[48]  K. Latham,et al.  Essential role of maternal UCHL1 and UCHL3 in fertilization and preimplantation embryo development , 2012, Journal of cellular physiology.

[49]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[50]  Je-Yoel Cho,et al.  Ubiquitin C‐terminal hydrolase‐L3 regulates Smad1 ubiquitination and osteoblast differentiation , 2011, FEBS letters.

[51]  X. Shen,et al.  The potential role of ubiquitin c-terminal hydrolases in oncogenesis. , 2010, Biochimica et biophysica acta.

[52]  K. Wada,et al.  Ubiquitin carboxyl-terminal hydrolase l3 promotes insulin signaling and adipogenesis. , 2009, Endocrinology.

[53]  Q. Zeng,et al.  A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.

[54]  M. Rapé,et al.  Mechanism of Ubiquitin-Chain Formation by the Human Anaphase-Promoting Complex , 2008, Cell.

[55]  E. Kebebew,et al.  Anaplastic thyroid carcinoma , 2005, Cancer.

[56]  Martin Rechsteiner,et al.  Recognition of the polyubiquitin proteolytic signal , 2000, The EMBO journal.